natgillin/translations-raw huggingface dataset:
wherein the method results in a therapeutic effect lasting for at least 3 months after cessation of therapy. The method of claim 14, wherein the C1-INH protein is plasma-derived or recombinant. 
C1-INH namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što postupak rezultira terapijskim učinkom koji traje najmanje 3 mjeseca nakon prekida terapije.
Once made, the cavity will absorb energy and grow. 
Kad je jedanput načinjena, šupljina će adsorbirati energiju i rasti.
Molecular weight: 296 g/mol Functionality: 1 
296 g/mol funkcionalnost: 1
A combination according to claim 12, wherein the pain is selected from inflammatory pain, neuropathic pain, acute pain, chronic pain, visceral pain, migraine pain and cancer pain. 
Kombinacija prema zahtjevu 9, naznačena time da je bol odabrana od upalne boli, neuropatske boli, akutne boli, kronične boli, visceralne boli, boli zbog migrene, te boli zbog karcinoma.
Group of containers assemblies (1) according to claim 11, wherein the container assemblies (1) are stacked in layers on a pallet (25) and juxtaposed assemblies (1) in a layer abut at their polygonal cross-sections. 
Skupina sklopova spremnika (1) prema zahtjevu 10, naznačena time što su sklopovi spremnika (1) složeni u slojevima na paleti (25) i naslagani sklopovi (1) u sloju se naslanjaju na njihovim poligonalnim poprečnim presjecima.
The method of claim 1, wherein the cumulative total amount of phosphorous per unit volume in said medium is greater than 5 mM. 
Postupak prema Zahtjevu 1, naznačen time, što je kumulativna ukupna količina fosfora po jedinici volumena u spomenutom mediju veća od približno 5 mM.
r is 0 or an integer from 1 to 20; 
r je 0 ili cijeli broj od 1 do 20;
The antibody of claim 7 comprising at least one of the group consisting of: a variable light chain comprising 
Protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što protutijelo sadrži najmanje jedno iz skupine koju čine:
The antibody, the conjugate, or the pharmaceutical composition of claim 21 wherein the cancer is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. The antibody, the conjugate, or the pharmaceutical composition of claims 21 or 22 wherein said CLD 18A2 is expressed on the surface of said cells. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 6 naznačeno time, što bolest ili poremećaj je bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz skupine koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma pankreasa, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave-vrata, karcinoma žučne vrećice i njihovih metastaza.
o R4, R5 and R6 are independently nitro, or o two adjacent substituents selected from R3, R4, R5, R6 and R7 may together with the carbon atoms they are attached to form a 5-7 membered, saturated or unsaturated ring containing carbon and optionally one or two heteroatoms selected from N, O or S, and optionally substituted with an (C1-C6) alkoxy group. 
HR P20120835 T1 oRa RsiReg su nezavisno nitro, ili o dva susjedna supstituenta izabrana između R3, R4, Rs, Rg 1 R; mogu zajedno s atomima ugljika za koji su spojeni formirati 5-7-eročlani, zasićeni ili nezasićeni prsten koji sadrži ugljik i po izboru jedan ili dva heteroatoma izabrana između N, O ili S, 1 po izboru je supstituiran skupinom (Ci-Cg) alkoksi.
The method of claim 1 wherein the mixed mode chromatography resin is a Capto™ MMC mixed mode chromatography resin or Capto™ Adhere mixed mode chromatography resin. 
Postupak sukladno zahtjevu 1, naznačen time da je smjesa miješane kromatografske smole Capto'" MMC mješovita kromatografska smola ili Capto"" Adhere mješovita kromatografska smola.
The method of paragraph 10, wherein the binding agent is present in an amount ranging from about 0.01 wt% to about 50 wt% of the formulation. 
Postupak prema zahtjevu 9, naznačen time da je sredstvo za vezanje prisutno u količini od 0,01 mas.% do 50 mas.% formulacije.
or a stereoisomer thereof. A compound according to claim 1 selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
After dilution with 3.6L of toluene, the mixture was cooled to 0-5°C prior to cautiously adding 7L of H2O at a rate such that the temperature did not exceed 10°C. 
Poslije razblažavanja sa 3.61 toluena, smjesa je hlađena do 0-5*C prije pažljivog dodavanja 71 H2O takvom stopom da temperatura nije prešla 10%C.
A composition comprising honey and a super-absorbent polymer fiber, which super-absorbent polymer fiber provides a lattice structure and is impregnated with the honey, wherein (a) the super-absorbent polymer fiber comprises a cross-linked polymer of acrylic acid and methacrylate; (b) the honey utilizes less than 50% of the super-absorbent polymer fiber's absorbent capacity; (c) the weight ratio of honey to super-absorbent polymer fiber is at least 2:1; and (d) the superabsorbent polymer fiber is able to absorb, in water, at least 10 times its dry weight whilst retaining structural integrity of the composition. 
HR P20170189 T1 PATENTNI ZAHTJEVI Obloga koja se sastoji od pripravka u obliku polukrutog savitljivog lista koji sadržava super-upijajuće vlakno kojim se formira rešetkasta struktura i koje je impregnirano medom, naznačena time, da je spomenuto super-upijajuće sredstvo super-upijajuće polimerno vlakno, pri čemu je super-upijajuće polimerno vlakno umreženi terpolimer akrilne kiseline, metilakrilat i mala količina monomera akrilata/metakrilata u kojem je akrilna kiselina djelomično neutralizirana u natrijevu sol akrilne kiseline.
By way of example, an even value of the quantized residue is associated with the index MVComp of value 0, while an odd value of the quantized residue is associated with the index MVComp of value 1. 
predznak prvog nenultog koeficijenta je pozitivan kada navedeni zbroj koeficijenata ima parnu vrijednost, dok je predznak prvog nenultog koeficijenta negativan kada navedeni zbroj koeficijenata ima neparnu vrijednost.
The resin-linked linear hexapeptides are assembled manually in the C- to N direction by iterative coupling reactions in a stirred batch reactor equipped with sintered glass frit under nitrogen. 
Na smolu vezani linearni heksapeptidi su sklopljeni manualno u C prem N smjeru u ponavljajućim reakcijama kupiranja u miješanom šaržnom reaktoru opremljenim = sinteriranom = staklenom = fritom pod atmosferom = dušika.
inserting a first filler material into the mold cavity, the first filler material encapsulating at least a portion of the first section of each of the plurality of lattice trusses; 
umetanje prvog punjenja (101) u kalup, pri čemu prvo punjenje (101) sadrži barem dio više rešetkastih nosača (102);
In another embodiment of the present disclosure, the cotton is selected from a group comprising natural cotton, surgical cotton, clinical grade cotton, commercial cotton, spun cotton, water washed cotton, acid or base washed cotton, autoclaved cotton, buffer treated cotton having pH ranging from about 1 to about 14, salt solution treated cotton, organic solvent treated cotton, pressed cotton and processed cotton. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se pamuk bira iz skupine koju čine prirodni pamuk, kirurški pamuk, pamuk kliničke kvalitete, komercijalni pamuk, predeni pamuk, pamuk pran vodom, pamuk pran kiselinom ili bazom, autoklavirani pamuk, puferirani pamuk s pH u rasponu od otprilike 1 do otprilike 14, pamuk obrađen otopinom soli, pamuk obrađen organskim otapalom, tiješteni pamuk i prerađeni pamuk.
The process of claim 20, further comprising recycling at least a portion of the first separation product to the reforming step. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time, da nadalje obuhvaća ponovnu upotrebu barem dijela (32) prvog proizvoda odvajanja (64) u reakcijskom koraku.
is 1 to 8 amino acid residues in length; and 
je duljine 1 do 8 ostataka amino kiseline; i
The PLP located in the third data region of the signal frame is acquired (S547). 
.... j 7 etjacanja PLE smještenog u trećem područiu podataka okvira signala postizanje transporta toka iz PLP
The scaffold of claim 1, wherein said scaffold comprises a cytokine, a bone morphogenetic protein (BMP), a chelator, a cell population, a therapeutic compound, or an antibiotic, or any combination thereof. 
Bioskela sukladno zahtjevu 3, pri čemu navedena obloga od polimera uključuje citokin, koštani morfogenetski protein (BMP), helator, populaciju stanica, terapeutsko sredstvo, antibiotik ili bilo koju njihovu kombinaciju.
Fatty acid derivatives have a long history in coatings and the incorporation of them into coating resins via esterification/transesterification is well documented. 
Derivati masnih kiselina imaju dugačku povijest u prevlakama i njihova ugradnja u smole za prevlake putem esterifikacije/transesterifikacije je dobro dokumentirana.
The composition of claim 1, obtained by polymerization or covalent bound formation between the constituents of two preparations a and b, wherein the preparation a has at least 1% of glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines, or chemically modified glycosaminoglycan, hydrolyzed glycosaminoglycans, glycosamines with cyclic polycarbonates or with Pre-polymer of polyhydroxyurethanes terminated by cyclic carbonates functions (PRE-CC) or a blend of those different constituents in a blend containing acceptable solvents and optionally CC monomers of PHU or PRE-CC or a blend of PRE-CC and CC to ensure that the preparation a contains cyclic carbonate functions, and 
Sastav prema zahtjevu 1 ili 2, dobiven polimerizacijom ili kovalentno vezanom formacijom između sastojaka dvaju pripravaka a 1 b, u kojem - - pripravak a ima barem 1 % glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina ili kemijski modificiranih glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina s cikličkim polikarbonatima ili s Pre-polimerom polihidroksiuretana terminiranog funkcijama cikličkih karbonata (PRE- CC) ili mješavinu spomenutih različitih sastojaka u mješavini koja sadrži prihvatljiva otapala i izborno CC monomere od PHU ili PRE-CC 1li mješavinu PRE-CC 1 CC kako bi se osiguralo da pripravak a sadrži funkcije cikličkih karbonata, i -
roller compacting the formulation prepared during step (a) with a compaction force comprised between 10 and 16 KN and; 
(b) sabijanja valjkom formulacije pripremljene tijekom koraka (a) silom sabijanja obuhvaćenom između 10 i 16 KN; te
The compound for use according to claim 1 or 2, characterized in that the pain is a nociceptive pain, an inflammatory pain, a neuropathic pain, an idiopathic pain or a psychogenic pain, preferably an inflammatory pain or neuropathic pain. 
Spoj za upotrebu prema patentnom zahtjevu 1, naznačen time da bol jest nociceptivna bol, upalna bol, neuropatska bol, idiopatska bol ili psihogena bol, preferirano upalna bol ili neuropatska bol.
Process according to claim 1, comprising a step wherein said slag is removed and is used as a source of magnesium, silica or both. 
Postupak u skladu sa zahtjevom 1, koji sadrži korak u kojem se navedena troska uklanja i koristi kao izvor magnezija, silicija ili oba.
One particularly important area is the development of drugs having improved MDR reversal properties. 
Jedno naročito važno područje je razvoj lijekova koji imaju poboljšana svojstva poništavanja MDR.
Apparatus according to claim 2 wherein the controller controls the third heat exchanger to heat air inside the greenhouse when temperature of the inside air drops below a predetermined minimum air temperature. Apparatus according to claim 1 wherein in the maintenance mode the controller controls the fan systems of the first and second heat exchangers to draw air from outside to inside the greenhouse at an average flow rate that is substantially proportional to a volume of the greenhouse. 
Uređaj prema bilo kojem od zahtjeva 2 do 4, pri čemu kontrolor upravlja trećim izmjenjivačem topline tako da on zagrijava zrak unutar staklenika kada temperatura unutrašnjeg zraka padne ispod unaprijed određene minimalne Uređaj prema bilo kojem od prethodnih zahtjeva, pri čemu u radnom režimu održavanja kontrolor upravlja ventilatorskim sistemom prvog i drugog izmjenjivača topline tako da usisava zrak iz okoliša u unutrašnjost staklenika sa prosječnim protokom koji je u suštini proporcionalan zapremini staklenika.
The method according to claim 8, wherein the therapy comprises administration of an anti-CD20 and/or anti-CD37 monoclonal antibody prior to the treatment with the radioimmunoconjugate. 
Radioimunokonjugat za primjenu u skladu sa zahtjevima 9 ili 10, naznačen time što se terapija sastoji od tretmana primjenom - anti-CD20 antitijela i/ili -anti-CD37 monoklonskog antitijela koji prethodi tretmanu radioimunokonjugatom, u skladu sa bilo kojim od zahtjeva 1-3.
adding a solution of BF3·Et2O in anhydrous dichloromethane dropwise with stirring over 1 hour to a solution of (±)-Cannabidiol in anhydrous dichloromethane at -5°C, stirring the resultant mixture for 1.5 hours at -5°C, adding the mixture to 7% NaHCO3, and isolating from the organic phase the crude trans-(±)-A9-tetrahydrocannabinol used in step (2). 
dodavanje otopine BF3·Et2O u bezvodnom diklorometanu kap po kap uz miješanje tijekom 1 sata u otopinu (±)-kanabidiola u bezvodnom diklorometanu na -5°C, miješanje nastale smjese tijekom 1.5 sata na -5°C, dodavanje smjese u 7% NaHCO3, te izoliranje iz organske faze sirovog trans-(±)-A9-tertahidrokanabinola koji je korišten u koraku (2).
A compound according to claim 1, selected from: 
Spoj prema zahtjevu 1 izabran od: mI
The tablet could not be comminuted using a hammer, nor with the assistance of a mortar and pestle. 
Tableta se nije mogla usitniti čekićem. Ovo također nije bilo moguće pomoću mužara i tučka.
In one embodiment, the peptide consists of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5 or a variant of said amino acid sequence. 
Peptid sukladno patentnom zahtjevu 1, sastavljen od aminokiselinske sekvence odabranu iz skupine sastavljene od SEK ID BR: 3, 41 5.
allowing the monoclonal antibody or functional part thereof to bind to amyloid protein to form an immunological complex; 
omogućavanje antitijelu da se veže za amiloidni antigen tako da se formira imunološki kompleks;
The locant of R4 is preferably 2-position or 3-position, with 2-position being particularly preferred. Each of R5 and R6 is preferably a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or a C1-3 alkoxy group. 
R'iR* koji mogu biti identični ili različiti jedan od drugog, predstavljaju atom vodika, atom halogena, C;.g alkil skupinu, koja može imati atom halogena kao supstituent, ili C1-3 alkil skupinu ili njihovu sol.
A pharmaceutical composition comprising the compound or a salt thereof according to claim 7, and a pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj ili njegovu so! prema zahtjevu 7, i farmaceutski prihvatljivo pomoćno sredstvo.
The present invention encompasses the introduction into beverages or foodstuffs of both synthetic (artificial) and natural N-heterocyclic substances, the latter being most preferred. 
Ovaj izum obuhvaća uvođenje u pića ili prehrambene proizvode i sintetskih (umjetnih) i prirodnih N-heterocikličkih tvari, posljednje su najpoželjnije.
The agent according to claim 5, wherein the agent is for treating symptoms associated with spinal canal stenosis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje simptoma povezanih sa stenozom kralježničnog kanala.
The compound according to claim 1, wherein R2 represents a halogen atom, a hydroxy group, or a linear or branched (C1-C6)alkoxy group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da R2 predstavlja atom halogena, hidroksi skupinu, ravnu ili razgrananu (C1-C6)alkoksi skupinu.
The method of E 8, wherein the IL-17 antagonist is a humanized monoclonal antibody or a fully human monoclonal antibody. 
1L-17 antagonist za uporabu u skladu sa zahtjevom 8, naznačen time, da IL-17 antagonist je humanizirano monoklonsko antitijelo ili potpuno ljudsko monoklonsko antitijelo.
An isolated population of cells comprising adherent stromal cells of placental tissue grown in a three-dimensional culture, wherein said adherent cells 
Izolirana populacija stanica koja sadrži adherentne stromalne stanice tkiva posteljice uzgojene u trodimenzionalnoj kulturi, naznačena time da navedene adherentne stanice
A combination for use according to claim 9 wherein the disorder mediated by inappropriate PI3-kinase activity is COPD. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze COPD.
and R11, for each occurrence, are independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl; or R10 and R11, taken together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl or an optionally substituted heteroaryl. 
i R11,su u svakom slučaju nezavisno –H, opcijski supstituirani alkil, opcijski supstituirani alkenil, opcijski supstituirani alkinil, opcijski supstituirani cikloalkil, opcijski supstituirani cikloalkenil, opcijski supstituirani heterociklil, opcijski supstituirani aril, opcijski supstituirani heteroaril, opcijski supstituirani aralkil, ili opcijski supstituirani heteraralkil; ili R10 i R11čine zajedno sa dušikom za koji su vezani opcijski supstituirani heterociklil ili opcijski supstituirani heteroaril;
The E. coli host cell of claim 1, wherein the nucleic acid encoding the anti-Factor D antibody or the anti-Factor D antibody fragment is selected from the group consisting of a nucleic acid encoding the amino acid sequence of SEQ ID NO:48, and a nucleic acid encoding the amino acid sequence of SEQ ID NO:49. 
Postupak prema patentnom zahtjevu 6, naznačen time, da protutijelo ili fragment protutijela je anti-VEGF protutijelo ili fragment anti-VEGF protutijela. Postupak prema patentom zahtjevu 7, naznačen time, da je nukleinska kiselina koja kodira anti-VEGF protutijelo ili fragment anti-VEGF protutijela, nukleinska kiselina koja kodira aminokiselinsku sekvencu ID BR.
Fig. 2 is a perspective view of a device for the friction spinning method. 
Slika 2 je pogled u perspektivi na uređaj za provođenje postupka frikcijskog predenja.
This is because, as noted, it is important for the connection between the jar mandrel 13 and the latch sub 14 to release, before the strain in the wireline causes rupturing of the wireline itself. 
Kao što je već bilo rečeno, za vezu između vretena 13 udaraca i elementa 14 zasuna važno je da se razdvoji prije nego što opterećenje u žicanoj vezi izazove sam njen prekid.
The stripping composition of claim 1, wherein the at least one pH-active agent is lactic acid. 
Sastav za skidanje u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da je najmanje jedno pH aktivno sredstvo je mliječna kiselina.
This assay measures the ability of a test compound to inhibit the proliferation of KB cells (human naso-pharangeal carcinoma obtained from the American Type Culture Collection (ATCC). 
Ovim testom mjeri se sposobnost ispitivanog spoja da inhibira proliferaciju KB stanica (stanice humanog nazofarangealnog karcinoma dobivene iz American Type Culture Collection (ATCC)).
cAMP standards and Detection Buffer (comprising 2 µCi of tracer [125I]-cAMP (100 µl) to 11 ml Detection Buffer) were prepared and maintained in accordance with the manufacturer's instructions. 
cAMP standard i Detekcijski Pufer (koji sadrži ŽuCi označenog ['*I]-cAMP u 11 ml Detekcijkog Pufera) su pripremljeni i čuvani u skladu s uputama proizvođača.
Apparatus as in claim 4 and 8, characterized in that said actuator (28) is connected to said mandrel (17) and is configured to move the latter and said second bending member (27) in said transverse direction (T). 
Uređaj prema zahtjevu 4 1 8, naznačen time da je navedeni aktuator (28) spojen na navedeno vreteno (17) i oblikovan je tako da potiskuje potonji i navedeni drugi element za savijanje (27) u navedenom poprečnom smjeru (T).
from about 10% to about 40% by weight of cinacalcet HCl; 
(a) od 10% do 40% težinski simakalcet HCiI;
The fusion protein for use according to any one of claims 1-2, wherein the interleukin 10 is fused N-terminal of the interleukin 4, optionally via a linker. 
Fuzijski protein namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što je interleukin 10 fuzioniran s N-krajem interleukina 4, izborno preko spojnice.
The receiver of claim 5, further comprising: a time-frequency deinterleaver configured to time-frequency deinterleave constellation values corresponding to PLP data; 
dio za raspletanje frekvencije (r709) konfiguriran za raspletanje frekvencije konstelacijskih vrijednosti koje odgovaraju podatku cijevi fizičke razine nazvanom PLP podatak;
The composition according to any one of claims 1 to 4, comprising botulinum toxin, trehalose, poloxamer 188, and methionine, wherein the relative weight amounts (%, w/w) of trehalose, poloxamer 188, and methionine are optionally within the following ranges: trehalose to 10 
Pripravak u skladu s patentnim zahtjevom 2, pri čemu količine relativne težine (%, w/w) trehaloze, poloksamera 188, metionina i opcionalno NaCl i opcionalno EDTA su: trehaloza ili saharoza 7 do 9 poloksamer 188 3.5 do 4.5 (nastavak) metionin 0.15 do 0.25;
blending raw materials with crystalline apixaban particles of controlled particle size to form a mix; 
miješanja sirovih materijala, sa apiksabanom kontrolirane veličine čestica;
The antibody according to claim to 4, which is an isolated monoclonal antibody, or an antigen-binding portion thereof, an antibody fragment, or an antibody mimetic. 
Protutijelo za uporabu sukladno zahtjevu 1 ili zahtjevu 2, koje je izolirano monoklonsko protutijelo ili njegov dio koji veže antigen, fragment protutijela.
The liquefied gas treatment system according to claim 1, wherein the third stream liquefied in the heat exchanger (21) is decompressed by decompressing means (22). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što je element za dekomprimiranje ekspanzijski ventil (22) ili ekspander (52).
a lid made of a plastic material and including a peripheral edge, the lid arranged so as to close the cup-shaped body; and 
- poklopca (5) koji je načinjen od plastičnog materijala i postavljen je na način da zatvara navedeno tijelo u obliku šalice (2);
Aaa′ is an amino acid residue selected from Ser, Asn or Thr; wherein the C-terminus thereof is a free terminus; 
Aaa je aminokiselinski ostatak, kojeg se bira između Ser i Thr; gdje je C-kraj slobodni kraj; i
P1-Har-Gly-Asp(O-P2)-Trp-Pro-OH to an activated cysteinamide residue through the Pro residue of the 2-6 eptifibatide fragment, thereby forming the 2-7 eptifibatide fragment. 
P,-Har-Gly-Asp(O-P>)-Trp-Pro-OH HR P20110812 TI na aktivirani reziduum cisteinamida putem rezidua Pro fragmenta 2-6 eptifibatida, čime se formira fragment 2-7 eptifibatida.
propyl substituted with C(=O)OR4, wherein R4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; or 
propil supstituiran sa C(=O)OR4, gdje je R4 alkil sa 1 do 18 ugljikovih atoma, alkenil sa 2 do 18 ugljikovih atoma, ili alkinil sa 2 do 18 ugljikovih atoma; ili